Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712491 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
A Phase 1 study, sponsored by Santen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00712491 is a Phase 1 study that was terminated before completion, run by Santen. The registered enrollment target is 20 participants.
The verdict
NCT00712491, a Phase 1 study, was terminated before completion, sponsored by Santen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.
Interventions
- DRUG Sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00712491
The ClinicalTrials.gov registry entry for NCT00712491 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sirolimus is the first listed.
NCT00712491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00712491 about?
NCT00712491 is a clinical study titled "Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration". The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.
What is the current status of trial NCT00712491?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2008-09. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00712491?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT00712491?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.